TABLE 2.
Efficacies of intraperitoneal buforin II, indolicidin, KFFKFFKFF and imipenem in a rat model of E. coli-induced peritonitis
| Treatment (dose [mg/kg])a | Lethalityb (no. of dead rats/ total no. [%]) | Qualitative blood culture (no. of positive cultures/ total no.) | Bacterial count (CFU/ml)c | Endotoxin concn (EU/ml)c | TNF-α concn (pg/ml)c |
|---|---|---|---|---|---|
| None (control group C1) | 15/15 (100) | 15/15 | 8.9 × 108 ± 2.2 × 108 | 0.218 ± 0.09 | 331.7 ± 77.3 |
| BUF II (1) | 4/15d (26.6) | 5/15d | 2.7 × 104 ± 0.7 × 104d | ≤0.015 ± 0.0d,e | 18.5 ± 2.7d,e |
| IND (1) | 6/15d (40.0) | 6/15d | 9.3 × 104 ± 2.4 × 104d | 0.096 ± 0.02d,f | 86.3 ± 11.8d,f |
| KFF (1) | 8/15d (53.3) | 9/15d | 5.2 × 105 ± 1.1 × 105d | 0.101 ± 0.02d,f | 107.4 ± 22.9d,f |
| IMP (20) | 2/15d,g (13.3) | 2/15d,g | 4.7 × 102 ± 1.2 × 102e,f | 0.211 ± 0.05 | 318.3 ± 63.1 |
a
The rats were administered E. coli (2 × 1010 CFU) intraperitoneally along with 1 ml of sterile saline solution. BUF II, buforin II; IND, indolicidin; KFF, KFFKFFKFF; IMP, imipenem.
b
Lethality was monitored for 72 h following the challenge.
c
The values are means ± SDs.
d
P < 0.05 versus control group C1.
e
P < 0.05 versus any other group.
f
P < 0.05 versus the imipenem-treated group.
g
P < 0.05 versus the peptide-treated groups.